Comparative review of pharmacological therapies in individuals with HER2 positive advanced breast cancer with focus on hormone receptor subgroup.

Chinyereugo M Umemneku-Chikere; Olubukola Ayodele; Marta Soares; Sam Khan; Keith Abrams; Rhiannon Owen; Sylwia Bujkiewicz

doi:10.3389/fonc.2022.943154

Comparative review of pharmacological therapies in individuals with HER2 positive advanced breast cancer with focus on hormone receptor subgroup.

Chinyereugo M Umemneku-Chikere, Olubukola Ayodele, Marta Soares, Sam Khan, Keith Abrams, Rhiannon Owen, Sylwia Bujkiewicz

Research output: Contribution to journal › Article › peer-review

Abstract

Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)-positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.

Original language	English
Article number	943154
Number of pages	12
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.943154 https://doi.org/10.3389/fonc.2022.943154
Publication status	Published - 18 Aug 2022

Bibliographical note

Access to Document

10.3389/fonc.2022.943154Licence: CC BY
10.3389/fonc.2022.943154

Revised Manuscript Untracked version
This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details
Accepted author manuscript, 751 KB
Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
© 2022 Umemneku-Chikere, Ayodele, Soares, Khan, Abrams, Owen and Bujkiewicz.
Final published version, 2.65 MBLicence: CC BY

Cite this

Umemneku-Chikere, C. M., Ayodele, O., Soares, M., Khan, S., Abrams, K., Owen, R., & Bujkiewicz, S. (2022). Comparative review of pharmacological therapies in individuals with HER2 positive advanced breast cancer with focus on hormone receptor subgroup. Frontiers in Oncology, 12, Article 943154. https://doi.org/10.3389/fonc.2022.943154, https://doi.org/10.3389/fonc.2022.943154

@article{097b16a655974780980132a22b3f5aef,

title = "Comparative review of pharmacological therapies in individuals with HER2 positive advanced breast cancer with focus on hormone receptor subgroup.",

abstract = "Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)-positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.",

author = "Umemneku-Chikere, {Chinyereugo M} and Olubukola Ayodele and Marta Soares and Sam Khan and Keith Abrams and Rhiannon Owen and Sylwia Bujkiewicz",

note = "{\textcopyright} 2022 Umemneku-Chikere, Ayodele, Soares, Khan, Abrams, Owen and Bujkiewicz. ",

year = "2022",

month = aug,

day = "18",

doi = "10.3389/fonc.2022.943154",

language = "English",

volume = "12",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Comparative review of pharmacological therapies in individuals with HER2 positive advanced breast cancer with focus on hormone receptor subgroup.

AU - Umemneku-Chikere, Chinyereugo M

AU - Ayodele, Olubukola

AU - Soares, Marta

AU - Khan, Sam

AU - Abrams, Keith

AU - Owen, Rhiannon

AU - Bujkiewicz, Sylwia

PY - 2022/8/18

Y1 - 2022/8/18

N2 - Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)-positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.

AB - Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)-positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.

U2 - 10.3389/fonc.2022.943154

DO - 10.3389/fonc.2022.943154

M3 - Article

C2 - 36059633

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 943154

ER -